Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Mary Christina Thomson | F | 53 | 2 years | |
Nick Glover | M | 55 | 6 years | |
Justin T. Huang | M | - | - | |
Robert E. Pelzer | M | 70 | 7 years | |
Andrew John MacDonald | M | 64 |
Cytopia Ltd.
Cytopia Ltd. Pharmaceuticals: MajorHealth Technology Cytopia Ltd. primarily engages in discovers and develops drugs to treat cancer and other diseases. The company commenced operations in 1997 in Melbourne, Australia, and has developed kinase enzyme biology and integrated a robust structural biology program with medicinal chemistry & drug development. The company conducts its research and drug development through subsidiaries based in Australia and the USA and also develops small molecule compounds with therapeutic profile for the treatment of cancer. The company has concluded two phase I safety and tolerability studies for its lead anticancer vascular disrupting agent, CYT997. It was founded on August 11, 1997 and is located in Melbourne, VI. | 6 years |
Stephen Dilly | M | 64 | 2 years | |
Emma McCann | F | - | 8 years | |
James Smith | M | 54 | 8 years | |
Georgia Erbez | F | 57 | 1 years | |
Christy Oliger | F | 54 | 1 years | |
Barbara Klencke | M | 66 | 7 years | |
Daniel J. Estes | M | 43 | 2 years | |
Christopher J. Burns | M | - |
Cytopia Ltd.
Cytopia Ltd. Pharmaceuticals: MajorHealth Technology Cytopia Ltd. primarily engages in discovers and develops drugs to treat cancer and other diseases. The company commenced operations in 1997 in Melbourne, Australia, and has developed kinase enzyme biology and integrated a robust structural biology program with medicinal chemistry & drug development. The company conducts its research and drug development through subsidiaries based in Australia and the USA and also develops small molecule compounds with therapeutic profile for the treatment of cancer. The company has concluded two phase I safety and tolerability studies for its lead anticancer vascular disrupting agent, CYT997. It was founded on August 11, 1997 and is located in Melbourne, VI. | 10 years |
Roderick Lyle | M | 69 |
Cytopia Ltd.
Cytopia Ltd. Pharmaceuticals: MajorHealth Technology Cytopia Ltd. primarily engages in discovers and develops drugs to treat cancer and other diseases. The company commenced operations in 1997 in Melbourne, Australia, and has developed kinase enzyme biology and integrated a robust structural biology program with medicinal chemistry & drug development. The company conducts its research and drug development through subsidiaries based in Australia and the USA and also develops small molecule compounds with therapeutic profile for the treatment of cancer. The company has concluded two phase I safety and tolerability studies for its lead anticancer vascular disrupting agent, CYT997. It was founded on August 11, 1997 and is located in Melbourne, VI. | 6 years |
Kevin Healey | M | 72 |
Cytopia Ltd.
Cytopia Ltd. Pharmaceuticals: MajorHealth Technology Cytopia Ltd. primarily engages in discovers and develops drugs to treat cancer and other diseases. The company commenced operations in 1997 in Melbourne, Australia, and has developed kinase enzyme biology and integrated a robust structural biology program with medicinal chemistry & drug development. The company conducts its research and drug development through subsidiaries based in Australia and the USA and also develops small molecule compounds with therapeutic profile for the treatment of cancer. The company has concluded two phase I safety and tolerability studies for its lead anticancer vascular disrupting agent, CYT997. It was founded on August 11, 1997 and is located in Melbourne, VI. | 14 years |
Alvin Vitangcol | M | 49 | 3 years | |
Nicole Onetto | M | 71 | 4 years | |
Craig Collard | M | 58 | 2 years | |
Wendi V. Rodrigueza | M | 58 | 10 years | |
Andrew Sinclair | M | 52 | 3 years | |
Gavan Flower | M | 51 |
Cytopia Ltd.
Cytopia Ltd. Pharmaceuticals: MajorHealth Technology Cytopia Ltd. primarily engages in discovers and develops drugs to treat cancer and other diseases. The company commenced operations in 1997 in Melbourne, Australia, and has developed kinase enzyme biology and integrated a robust structural biology program with medicinal chemistry & drug development. The company conducts its research and drug development through subsidiaries based in Australia and the USA and also develops small molecule compounds with therapeutic profile for the treatment of cancer. The company has concluded two phase I safety and tolerability studies for its lead anticancer vascular disrupting agent, CYT997. It was founded on August 11, 1997 and is located in Melbourne, VI. | - |
Geoffrey Norman Vaughan | M | 91 |
Cytopia Ltd.
Cytopia Ltd. Pharmaceuticals: MajorHealth Technology Cytopia Ltd. primarily engages in discovers and develops drugs to treat cancer and other diseases. The company commenced operations in 1997 in Melbourne, Australia, and has developed kinase enzyme biology and integrated a robust structural biology program with medicinal chemistry & drug development. The company conducts its research and drug development through subsidiaries based in Australia and the USA and also develops small molecule compounds with therapeutic profile for the treatment of cancer. The company has concluded two phase I safety and tolerability studies for its lead anticancer vascular disrupting agent, CYT997. It was founded on August 11, 1997 and is located in Melbourne, VI. | 13 years |
Mark Rowsthorn | M | 69 |
Cytopia Ltd.
Cytopia Ltd. Pharmaceuticals: MajorHealth Technology Cytopia Ltd. primarily engages in discovers and develops drugs to treat cancer and other diseases. The company commenced operations in 1997 in Melbourne, Australia, and has developed kinase enzyme biology and integrated a robust structural biology program with medicinal chemistry & drug development. The company conducts its research and drug development through subsidiaries based in Australia and the USA and also develops small molecule compounds with therapeutic profile for the treatment of cancer. The company has concluded two phase I safety and tolerability studies for its lead anticancer vascular disrupting agent, CYT997. It was founded on August 11, 1997 and is located in Melbourne, VI. | 13 years |
Donald Parfet | M | 71 | 4 years | |
Albert Cha | M | 51 | 2 years | |
James Topper | M | 62 | 3 years | |
Peter Thompson | M | 64 | 1 years | |
Andrew Allen | M | 57 | 5 years | |
Gaurav Aggarwal | M | 51 | 3 years | |
Mona Ashiya | M | 55 | 3 years | |
Kevin Thomas Ryan | M | - | - | |
Jeffrey Cooper | M | 68 | 6 years | |
Tran Nguyen | M | 50 | 3 years | |
Diane Gardiner | F | - | - | |
Amy Barrier Altshul | F | - | - | |
Lauren Rose Musto | F | - | 1 years | |
Christian Hassig | M | 52 | - | |
Josh Richardson | M | 42 | 3 years | |
Simon Eastman | M | - | - | |
Kevin Norrett | M | 51 | 2 years | |
Keith E. Anderson | M | 55 | 7 years | |
Sukhi Jagpal | M | 50 | 7 years | |
Wendy Chapman | F | 58 | 8 years | |
Chandra D. Lovejoy | F | 52 | 3 years | |
Mark Kowalski | M | 69 | 5 years | |
William D. Turner | M | 58 | 2 years | |
Angie You | M | 51 | 4 years | |
Richard A. Messmann | M | 67 | 4 years | |
Robert Watson | M | 68 |
Cytopia Ltd.
Cytopia Ltd. Pharmaceuticals: MajorHealth Technology Cytopia Ltd. primarily engages in discovers and develops drugs to treat cancer and other diseases. The company commenced operations in 1997 in Melbourne, Australia, and has developed kinase enzyme biology and integrated a robust structural biology program with medicinal chemistry & drug development. The company conducts its research and drug development through subsidiaries based in Australia and the USA and also develops small molecule compounds with therapeutic profile for the treatment of cancer. The company has concluded two phase I safety and tolerability studies for its lead anticancer vascular disrupting agent, CYT997. It was founded on August 11, 1997 and is located in Melbourne, VI. | 6 years |
Alexandra Marie Nieves Gonzalez | F | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 42 | 84.00% |
Australia | 8 | 16.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Gregg Smith
- Personal Network